
Sign up to save your podcasts
Or
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
4.5
236236 ratings
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
43,926 Listeners
30,965 Listeners
32,137 Listeners
26,166 Listeners
59,384 Listeners
4,119 Listeners
9,535 Listeners
9,530 Listeners
572 Listeners
14,398 Listeners
6,246 Listeners
5,092 Listeners
405 Listeners
73 Listeners
1,833 Listeners
4,747 Listeners
2,140 Listeners
80 Listeners
427 Listeners
235 Listeners
1,221 Listeners
265 Listeners
232 Listeners
434 Listeners
148 Listeners
366 Listeners
331 Listeners
31 Listeners
96 Listeners
1,591 Listeners
77 Listeners
258 Listeners
252 Listeners